Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 100 of 196 results for sepsis

  1. Bronchiolitis in children: diagnosis and management (NG9)

    This guideline covers diagnosing and managing bronchiolitis in babies and children. It aims to help healthcare professionals diagnose bronchiolitis and identify if babies and children should be cared for at home or in hospital. It describes treatments and interventions that can be used to help with the symptoms of bronchiolitis.

  2. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  3. Inducing labour (NG207)

    This guideline covers the circumstances for inducing labour, methods of induction, assessment, monitoring, pain relief and managing complications. It aims to improve advice and care for pregnant women who are thinking about or having induction of labour.

  4. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

  5. Utilising the skills of the clinical pharmacist within the MDT for improved medicines optimisation

    protocol for intra-abdominal sepsis. Switch from IV to PO. Significant interventions Patient treated for abdominal sepsis...

  6. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

  7. RespiraSense for continuously monitoring respiratory rate (MIB299)

    NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .

  8. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    These serious complications include severe bleeding, damage to the womb or sepsis (a severe reaction to an infection). The risk of...

  9. Impact of pharmacist involvement in enhanced recovery pathways in improving patient care in those undergoing lower gastrointestinal surgery

    management / extended opioid use / suboptimal dose / dose too high Sepsis (Urosepsis / HAP / sepsis of unknown origin)...

  10. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

  11. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (IPG232)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

  12. Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option (IPG764)

    Evidence-based recommendations on endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. This involves inserting a stent through an endoscope into the gallbladder.

  13. Neonatal infection (QS75)

    This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.

  14. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  15. Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)

    This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.

  16. NICE impact diagnostic pathology

    Find out more about the progress made in implementing NICE guidance on diagnostic pathology

  17. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

  18. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    Evidence-based recommendations on extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

  20. Cerebral palsy in children and young people (QS162)

    This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.

  21. Jaundice in newborn babies under 28 days (CG98)

    This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.

  22. Midcarpal hemiarthroplasty for wrist arthritis (IPG663)

    Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.

  23. National Early Warning Score systems that alert to deteriorating adult patients in hospital (MIB205)

    NICE has developed a medtech innovation briefing (MIB) on National Early Warning Score systems that alert to deteriorating adult patients in hospital .

  24. Accreditation

    NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.

  25. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  26. Total wrist replacement (IPG271)

    Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.

  27. Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)

    NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .

  28. Adalimumab for the treatment of adults with psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

  29. Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.

  30. Use of biomarkers to diagnose and initiate treatment:- What is the clinical and cost effectiveness of procalcitonin (PCT) point-of-care tests at initial triage for diagnosis of serious infection and the initiation of appropriate antibiotic therapy?

    monitoring sepsis has shown there is not enough evidence in this area. Source guidance details Comes from guidance Suspected...

  31. Negative pressure wound therapy for the open abdomen (IPG467)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

  32. Consensus based national antimicrobial stewardship competencies for UK undergraduate healthcare professional education

    Principles of prescribing in Infection; 2) Infection in Secondary Care; and 3) Sepsis. The modules are also available to 14 UK Medical...

  33. Bioprosthetic plug insertion for anal fistula (IPG662)

    Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in place.

  34. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  35. Collagen paste for closing an anal fistula (IPG648)

    Evidence-based recommendations on collagen paste for closing an anal fistula in adults. This involves using the paste to fill the fistula to seal it. The aim is to encourage healing.

  36. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  37. Radially emitting laser fibre treatment of an anal fistula (IPG644)

    Evidence-based recommendations on radially emitting laser fibre treatment of an anal fistula in adults. This involves applying laser energy to the fistula.

  38. Diabetic foot problems: prevention and management (NG19)

    This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.

  39. Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis (IPG720)

    Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction.

  40. Percutaneous thoracic duct embolisation for persistent chyle leak (IPG755)

    Evidence-based recommendations on percutaneous thoracic duct embolisation for persistent chyle leak. In this procedure, under general anaesthesia, ultrasound and X-rays are used to create an image of the thoracic duct and find the leak. Then, using a needle, a tube is inserted through the abdominal wall (percutaneous) and guided into the thoracic duct. Small metal coils and medical glue are inserted through the tube and used to plug the leak (embolisation). The aim is to stop the leak.

  41. Fallopian tube recanalisation by guidewire (IPG71)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this doesn't unblock it, using a guidewire.

  42. Kurin Lock for blood culture collection (MTG77)

    Evidence-based recommendations on Kurin Lock for blood culture collection.

  43. Intravenous fluid therapy in children and young people in hospital (QS131)

    This quality standard covers managing intravenous (IV) fluids safely and effectively for babies, children and young people (from birth to 16) in hospital. It describes high-quality care in priority areas for improvement.

  44. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  45. Temperature control to improve neurological outcomes after cardiac arrest (IPG782)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

  46. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG688)

    Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves surgically removing visible cancer and bathing the abdominal cavity with heated chemotherapy fluid to reach any remaining cancer cells.